Moderna Sales Get Lift From Early Nod

Moderna reports surprise profit on higher-than-expected COVID vaccine sales
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial virus shot.
Moderna sales get lift from early nod for newest COVID shot
Moderna delivered better-than-expected profit and sales in the third quarter after an early start to sales of this season’s COVID boosters.
Moderna Stock Gains on Better-Than-Expected Covid-19 Vaccine Sales
Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed its full-year sales forecast. Covid vaccine sales totaled $1.8 billion for the third quarter.
Moderna Gets Better-Than-Expected Q3 COVID-19 Vaccine Sales, but RSV Shot Disappoints
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday note to investors said sales of the company’s respiratory syncytial virus vaccine mRESVIA was significantly lower than expected.
Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. | Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines,
Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold
Moderna on Thursday posted a surprise profit for the third quarter, smashing Wall Street estimates, as its cost-cutting efforts took hold and sales of its Covid vaccine came in higher than expected.
Moderna posts surprise profit as COVID vaccine sales exceed expectations
Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of its COVID-19 vaccine.
Moderna, Pfizer or Novavax? How the three Covid-19 vaccines differ according to Yale Medicine
In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three vaccines available in the U.S.
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
BioPharma Dive1d
Moderna earnings beat forecasts, but analysts question whether sales spike will last
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
Seeking Alpha on MSN2d
Moderna swings to profits as new COVID shot powers Q3 beat
Shares of Moderna (NASDAQ:MRNA) traded ~7% higher in the premarket on Thursday after the company swung back to profits on ...
Moderna EPS Beats Estimates, Sales Rise
Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...
Stocktwits on MSN3d
Moderna Stock Slips On Report Of CEO Relinquishing Sales Chief Role: Retail Mood Dims
Shares of Moderna, Inc. ($MRNA), among the frontrunners in mRNA vaccine technology, fell on Tuesday, bucking the broader market strength. The weakness came after Bloomberg reported, citing a person ...
NBC News on MSN6d
Some people will need an extra Covid vaccine in the spring
In October, the Centers for Disease Control and Prevention recommended that high-risk adults get a second updated Covid ...